-- 2026年4月27日，首席策略長兼董事布萊恩·M·文圖羅(Brian M. Venturo)出售了CoreWeave (CRWV)的375,000股股票，套現40,887,640美元。根據向美國證券交易委員會(SEC)提交的4號表格文件，文圖羅目前控制該公司共計411,446股A類普通股，其中223,580股為直接持有，187,866股為間接控制。 SEC文件連結： https://www.sec.gov/Archives/edgar/data/1769628/000176962826000209/xslF345X05/form4.xml
Related Articles
Research
Research Alert: Blue Owl Capital Reports Slight Distributable Earnings Beat And Aum Growth
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OWL delivered Q1 2026 FRE of $0.25 vs $0.23 consensus and DE of $0.19 vs $0.18 consensus, with LTM FRE revenues up 13% and FRE up 14% Y/Y. AUM rose 15% Y/Y to $315B though sequential growth was limited by redemptions, while fee-paying AUM reached $188B, up 7% Y/Y. We believe OWL is well-positioned for the secular shift to private credit and is diversifying beyond its leading credit position across multiple debt financing categories. Management noted software loan balances represent only 8% of total AUM, addressing market concerns, but provided no specific financial guidance. The annual dividend increased 25% Y/Y to $0.90 per share in 2025, and the company repurchased 1.7M shares for $25M in Q1 2026. We expect positive AUM trends to continue as new capital raised was more than double fund distributions. Despite share price volatility from direct lending concerns, we would stay the course with OWL shares given strong fundamentals.
$OWL
Research
Research Alert: Bax Q1: Mixed Results Amid Operational Challenges And Transformation Efforts
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Baxter delivered mixed Q1 2026 results with sales of $2.7B (+3% reported, -1% organic) beating consensus by $80M, though organic decline highlighted execution issues. Adjusted EPS of $0.36 beat expectations by $0.05 but declined 35% Y/Y due to unfavorable expense timing and higher manufacturing costs. We view the persistent operational challenges across key divisions as concerning despite management's transformation efforts. Management reiterated full-year 2026 guidance of flat to 1% sales growth and adjusted EPS of $1.85-$2.05, emphasizing progress on the Baxter Growth and Performance System with 230+ Q1 initiatives. Segment performance remained mixed with Medical Products & Therapies generating $1.3B (+2% reported, -2% organic) hampered by infusion pump issues, while Pharmaceuticals provided strength at $621M (+7% reported). We believe the ongoing execution challenges underscore the complexity in stabilizing operations despite improved free cash flow of $76M vs. -$221M in the prior year.
$BAX
Research
Research Alert: Blue Owl Capital Reports Slight Distributable Earnings Beat And Aum Growth
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:OWL delivered Q1 2026 FRE of $0.25 vs $0.23 consensus and DE of $0.19 vs $0.18 consensus, with LTM FRE revenues up 13% and FRE up 14% Y/Y. AUM rose 15% Y/Y to $315B though sequential growth was limited by redemptions, while fee-paying AUM reached $188B, up 7% Y/Y. We believe OWL is well-positioned for the secular shift to private credit and is diversifying beyond its leading credit position across multiple debt financing categories. Management noted software loan balances represent only 8% of total AUM, addressing market concerns, but provided no specific financial guidance. The annual dividend increased 25% Y/Y to $0.90 per share in 2025, and the company repurchased 1.7M shares for $25M in Q1 2026. We expect positive AUM trends to continue as new capital raised was more than double fund distributions. Despite share price volatility from direct lending concerns, we would stay the course with OWL shares given strong fundamentals.
$OWL